Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
55.99
-0.44 (-0.78%)
At close: Jan 16, 2026, 4:00 PM EST
56.87
+0.88 (1.57%)
After-hours: Jan 16, 2026, 7:08 PM EST
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $143.00K in the quarter ending September 30, 2025. In the year 2024, Crinetics Pharmaceuticals had annual revenue of $1.04M, down -74.11%.
Revenue (ttm)
$1.04M
Revenue Growth
-74.11%
P/S Ratio
3,739.18
Revenue / Employee
$3,513
Employees
437
Market Cap
5.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
| Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
| Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
| Dec 31, 2016 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRNX News
- 6 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript - Seeking Alpha
- 14 days ago - Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia - GlobeNewsWire
- 15 days ago - Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire